Cargando…

A Molecular Model for Predicting Overall Survival in Patients with Metastatic Clear Cell Renal Carcinoma: Results from CALGB 90206 (Alliance)

BACKGROUND: Prognosis associated with metastatic renal cell carcinoma (mRCC) can vary widely. METHODS: This study used pretreatment nephrectomy specimens from a randomized phase III trial. Expression levels of candidate genes were determined from archival tumors using the OpenArray® platform for Taq...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Hyung L., Halabi, Susan, Li, Ping, Mayhew, Greg, Simko, Jeff, Nixon, Andrew B., Small, Eric J., Rini, Brian, Morris, Michael J., Taplin, Mary-Ellen, George, Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4740313/ https://www.ncbi.nlm.nih.gov/pubmed/26870806 http://dx.doi.org/10.1016/j.ebiom.2015.09.012

Ejemplares similares

Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance)
por: Brown, Justin C, et al.
Publicado: (2019)

Body Mass Index and Weight Loss in Metastatic Colorectal Cancer in CALGB (Alliance)/SWOG 80405
por: Guercio, Brendan J, et al.
Publicado: (2020)

Blood‐based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance)
por: Hatch, Ace J., et al.
Publicado: (2016)

IGF-Binding Proteins, Adiponectin, and Survival in Metastatic Colorectal Cancer: Results From CALGB (Alliance)/SWOG 80405
por: Guercio, Brendan J, et al.
Publicado: (2020)

Sugar-Sweetened Beverage Intake and Cancer Recurrence and Survival in CALGB 89803 (Alliance)
por: Fuchs, Michael A., et al.
Publicado: (2014)

Race, Income, and Survival in Stage III Colon Cancer: CALGB 89803 (Alliance)
por: Lee, Seohyuk, et al.
Publicado: (2021)

Grain Intake and Clinical Outcome in Stage III Colon Cancer: Results From CALGB 89803 (Alliance)
por: Brown, Justin C, et al.
Publicado: (2018)

Long‐term trajectories of self‐reported cognitive function in a cohort of older survivors of breast cancer: CALGB 369901 (Alliance)
por: Mandelblatt, Jeanne S., et al.
Publicado: (2016)

Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance)
por: Fadelu, Temidayo, et al.
Publicado: (2018)

Polygenic Inheritance of Paclitaxel-Induced Sensory Peripheral Neuropathy Driven by Axon Outgrowth Gene Sets in CALGB 40101 (Alliance)
por: Chhibber, Aparna, et al.
Publicado: (2014)

Androgen Decline and Survival During Docetaxel Therapy in metastatic Castration Resistant Prostate Cancer (mCRPC)
por: Ryan, Charles J, et al.
Publicado: (2019)

Associations of artificially sweetened beverage intake with disease recurrence and mortality in stage III colon cancer: Results from CALGB 89803 (Alliance)
por: Guercio, Brendan J., et al.
Publicado: (2018)

Marital Status, Living Arrangement, and Cancer Recurrence and Survival in Patients with Stage III Colon Cancer: Findings from CALGB 89803 (Alliance)
por: Lee, Seohyuk, et al.
Publicado: (2022)

Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update
por: Choueiri, Toni K., et al.
Publicado: (2018)

Randomisierte Phase-II-Studie zur an der PET-Response orientierten multimodalen Therapie des Speiseröhrenkrebses – Ergebnisse des CALGB 80803 (Alliance) Trial
por: Bauer, Lukas, et al.
Publicado: (2022)

CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer
por: Shepherd, Jonathan H., et al.
Publicado: (2022)

Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342
por: Harris, Lyndsay N, et al.
Publicado: (2006)

Updated analysis of CALGB 100104 (Alliance): a randomised phase III study evaluating lenalidomide vs placebo maintenance after single autologous stem cell transplant for multiple myeloma
por: Holstein, Sarah A., et al.
Publicado: (2017)

Corrigendum to ‘Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update’ [Eur J Cancer 94 (May 2018) 115–125]
por: Choueiri, Toni K., et al.
Publicado: (2018)

Age and the Risk of Paclitaxel‐Induced Neuropathy in Women with Early‐Stage Breast Cancer (Alliance A151411): Results from 1,881 Patients from Cancer and Leukemia Group B (CALGB) 40101
por: Barginear, Myra, et al.
Publicado: (2018)

Geriatric assessment for older adults receiving less-intensive therapy for acute myeloid leukemia: report of CALGB 361101
por: Ritchie, Ellen K., et al.
Publicado: (2022)

Outcomes of a Modified CALGB 19802 Regimen in Adult Acute Lymphoblastic Leukemia
por: Han, A-Reum, et al.
Publicado: (2008)

Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104)
por: Gajewski, Thomas F, et al.
Publicado: (2012)

Economic evaluation study (CHEER-compliant): Cost-effectiveness analysis of RAS screening for treatment of metastatic colorectal cancer based on the CALGB 80405 trial
por: Zhou, Jing, et al.
Publicado: (2016)

MRE11-Deficiency Associated with Improved Long-Term Disease Free Survival and Overall Survival in a Subset of Stage III Colon Cancer Patients in Randomized CALGB 89803 Trial
por: Pavelitz, Thomas, et al.
Publicado: (2014)

Characteristics of toxicity occurrence patterns in concurrent chemoradiotherapy after induction chemotherapy for patients with locally advanced non-small cell lung cancer: a pooled analysis based on individual patient data of CALGB/Alliance trials
por: Yang, Lexie Zidanyue, et al.
Publicado: (2022)

Treatment of adult Burkitt lymphoma with the CALGB 1002 protocol: a single center experience in Jordan
por: Ma’koseh, Mohammad, et al.
Publicado: (2021)

A modified CALGB 10403 in adolescents and young adults with acute lymphoblastic leukemia in Central America
por: Rangel-Patiño, Juan, et al.
Publicado: (2023)

Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial
por: George, Daniel J., et al.
Publicado: (2019)

Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer
por: Small, E J, et al.
Publicado: (2019)

The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials
por: Lansigan, Frederick, et al.
Publicado: (2018)

The impact of early PEG-asparaginase discontinuation in young adults with ALL: a post hoc analysis of the CALGB 10403 study
por: Aldoss, Ibrahim, et al.
Publicado: (2022)

Phase II Study of Everolimus in Metastatic Malignant Melanoma (NCCTG‐N0377, Alliance)
por: Vera Aguilera, Jesus, et al.
Publicado: (2018)

Somatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial Tumors
por: Bellmunt, Joaquim, et al.
Publicado: (2015)

Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial
por: Jahn, Nikolaus, et al.
Publicado: (2022)

High expression of galectin-7 associates with poor overall survival in patients with non-metastatic clear-cell renal cell carcinoma
por: Wang, Jieti, et al.
Publicado: (2016)

ACI Alliance – The American Cochlear Implant Alliance Foundation
por: Niparko, John K, et al.
Publicado: (2013)

Measuring Disease-Free Survival and Cancer Relapse Using Medicare Claims From CALGB Breast Cancer Trial Participants (Companion to 9344)
por: Lamont, Elizabeth B., et al.
Publicado: (2006)

Assessing the Impact of CALGB 9343 on Surgical Trends in Elderly-Women With Stage I ER+ Breast Cancer: A SEER-Based Analysis
por: Bazan, Jose G., et al.
Publicado: (2019)

Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials
por: Rediti, Mattia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_nucaqnquir6hdglfp4s57lmh77